Selected research
Industry Research
Migraine Drugs Industry Research Report 2026
Market perspective
The global Migraine Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Migraine Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Migraine Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Migraine Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Migraine Drugs include Abbott, Johnson & Johnson, Merck, Eli Lilly, Pfizer, Pfizer, Bayer, Winston Pharmaceuticals and Teva, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Migraine Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Migraine Drugs Market by Company
Abbott
Johnson & Johnson
Merck
Eli Lilly
Pfizer
Pfizer
Bayer
Winston Pharmaceuticals
Teva
Kowa Pharmaceuticals America
Impax
GlaxoSmithKline
Ethypharm
Endo International
AstraZeneca
Allergan
Migraine Drugs Segment by Type
Rizatriptan
Others Drug
Sumatriptan
Zolmitriptan
Migraine Drugs Segment by Application
Hospitals
Clinics
Household Use
Others
Migraine Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Migraine Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Migraine Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Migraine Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Migraine Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Migraine Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Migraine Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Rizatriptan
- Others Drug
- Sumatriptan
- Zolmitriptan
Applications
- Hospitals
- Clinics
- Household Use
- Others
Companies covered
- Abbott
- Johnson & Johnson
- Merck
- Eli Lilly
- Pfizer
- Pfizer
- Bayer
- Winston Pharmaceuticals
- Teva
- Kowa Pharmaceuticals America
- Impax
- GlaxoSmithKline
- Ethypharm
- Endo International
- AstraZeneca
- Allergan
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Migraine Drugs Market Size (2021-2032)
- 2.2.2 Global Migraine Drugs Sales (2021-2032)
- 2.2.3 Global Migraine Drugs Market Average Price (2021-2032)
- 2.3 Migraine Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Rizatriptan
- 2.3.3 Others Drug
- 2.3.4 Sumatriptan
- 2.3.5 Zolmitriptan
- 2.4 Migraine Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospitals
- 2.4.3 Clinics
- 2.4.4 Household Use
- 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Migraine Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Migraine Drugs Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Migraine Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Migraine Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Migraine Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Migraine Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Migraine Drugs, Product Type & Application
- 3.8 Global Manufacturers of Migraine Drugs, Established Date
- 3.9 Global Migraine Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Abbott
- 4.1.1 Abbott Company Information
- 4.1.2 Abbott Business Overview
- 4.1.3 Abbott Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Abbott Migraine Drugs Product Portfolio
- 4.1.5 Abbott Recent Developments
- 4.2 Johnson & Johnson
- 4.2.1 Johnson & Johnson Company Information
- 4.2.2 Johnson & Johnson Business Overview
- 4.2.3 Johnson & Johnson Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Johnson & Johnson Migraine Drugs Product Portfolio
- 4.2.5 Johnson & Johnson Recent Developments
- 4.3 Merck
- 4.3.1 Merck Company Information
- 4.3.2 Merck Business Overview
- 4.3.3 Merck Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Merck Migraine Drugs Product Portfolio
- 4.3.5 Merck Recent Developments
- 4.4 Eli Lilly
- 4.4.1 Eli Lilly Company Information
- 4.4.2 Eli Lilly Business Overview
- 4.4.3 Eli Lilly Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Eli Lilly Migraine Drugs Product Portfolio
- 4.4.5 Eli Lilly Recent Developments
- 4.5 Pfizer
- 4.5.1 Pfizer Company Information
- 4.5.2 Pfizer Business Overview
- 4.5.3 Pfizer Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Pfizer Migraine Drugs Product Portfolio
- 4.5.5 Pfizer Recent Developments
- 4.6 Pfizer
- 4.6.1 Pfizer Company Information
- 4.6.2 Pfizer Business Overview
- 4.6.3 Pfizer Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Pfizer Migraine Drugs Product Portfolio
- 4.6.5 Pfizer Recent Developments
- 4.7 Bayer
- 4.7.1 Bayer Company Information
- 4.7.2 Bayer Business Overview
- 4.7.3 Bayer Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Bayer Migraine Drugs Product Portfolio
- 4.7.5 Bayer Recent Developments
- 4.8 Winston Pharmaceuticals
- 4.8.1 Winston Pharmaceuticals Company Information
- 4.8.2 Winston Pharmaceuticals Business Overview
- 4.8.3 Winston Pharmaceuticals Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Winston Pharmaceuticals Migraine Drugs Product Portfolio
- 4.8.5 Winston Pharmaceuticals Recent Developments
- 4.9 Teva
- 4.9.1 Teva Company Information
- 4.9.2 Teva Business Overview
- 4.9.3 Teva Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Teva Migraine Drugs Product Portfolio
- 4.9.5 Teva Recent Developments
- 4.10 Kowa Pharmaceuticals America
- 4.10.1 Kowa Pharmaceuticals America Company Information
- 4.10.2 Kowa Pharmaceuticals America Business Overview
- 4.10.3 Kowa Pharmaceuticals America Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Kowa Pharmaceuticals America Migraine Drugs Product Portfolio
- 4.10.5 Kowa Pharmaceuticals America Recent Developments
- 4.11 Impax
- 4.11.1 Impax Company Information
- 4.11.2 Impax Business Overview
- 4.11.3 Impax Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Impax Migraine Drugs Product Portfolio
- 4.11.5 Impax Recent Developments
- 4.12 GlaxoSmithKline
- 4.12.1 GlaxoSmithKline Company Information
- 4.12.2 GlaxoSmithKline Business Overview
- 4.12.3 GlaxoSmithKline Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 GlaxoSmithKline Migraine Drugs Product Portfolio
- 4.12.5 GlaxoSmithKline Recent Developments
- 4.13 Ethypharm
- 4.13.1 Ethypharm Company Information
- 4.13.2 Ethypharm Business Overview
- 4.13.3 Ethypharm Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Ethypharm Migraine Drugs Product Portfolio
- 4.13.5 Ethypharm Recent Developments
- 4.14 Endo International
- 4.14.1 Endo International Company Information
- 4.14.2 Endo International Business Overview
- 4.14.3 Endo International Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Endo International Migraine Drugs Product Portfolio
- 4.14.5 Endo International Recent Developments
- 4.15 AstraZeneca
- 4.15.1 AstraZeneca Company Information
- 4.15.2 AstraZeneca Business Overview
- 4.15.3 AstraZeneca Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 AstraZeneca Migraine Drugs Product Portfolio
- 4.15.5 AstraZeneca Recent Developments
- 4.16 Allergan
- 4.16.1 Allergan Company Information
- 4.16.2 Allergan Business Overview
- 4.16.3 Allergan Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Allergan Migraine Drugs Product Portfolio
- 4.16.5 Allergan Recent Developments
5 Global Migraine Drugs Market Scenario by Region
- 5.1 Global Migraine Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Migraine Drugs Sales by Region: 2021-2032
- 5.2.1 Global Migraine Drugs Sales by Region: 2021-2026
- 5.2.2 Global Migraine Drugs Sales by Region: 2027-2032
- 5.3 Global Migraine Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Migraine Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Migraine Drugs Revenue by Region: 2027-2032
- 5.4 North America Migraine Drugs Market Facts & Figures by Country
- 5.4.1 North America Migraine Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Migraine Drugs Sales by Country (2021-2032)
- 5.4.3 North America Migraine Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Migraine Drugs Market Facts & Figures by Country
- 5.5.1 Europe Migraine Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Migraine Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Migraine Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Migraine Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Migraine Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Migraine Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Migraine Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Migraine Drugs Market Facts & Figures by Country
- 5.7.1 South America Migraine Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Migraine Drugs Sales by Country (2021-2032)
- 5.7.3 South America Migraine Drugs Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Migraine Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Migraine Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Migraine Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Migraine Drugs Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Migraine Drugs Sales by Type (2021-2032)
- 6.1.1 Global Migraine Drugs Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Migraine Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Migraine Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Migraine Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Migraine Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Migraine Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Migraine Drugs Sales by Application (2021-2032)
- 7.1.1 Global Migraine Drugs Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Migraine Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Migraine Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Migraine Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Migraine Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Migraine Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Migraine Drugs Value Chain Analysis
- 8.1.1 Migraine Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Migraine Drugs Production Mode & Process
- 8.2 Migraine Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Migraine Drugs Distributors
- 8.2.3 Migraine Drugs Customers
9 Global Migraine Drugs Analyzing Market Dynamics
- 9.1 Migraine Drugs Industry Trends
- 9.2 Migraine Drugs Industry Drivers
- 9.3 Migraine Drugs Industry Opportunities and Challenges
- 9.4 Migraine Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst